Novavax Management Discusses Q2 2012 Results - Earnings Call Transcript

Novavax (NVAX)

Q2 2012 Earnings Call

August 03, 2012 10:00 am ET

Executives

John A. Herrmann - Vice President, General Counsel and Corporate Secretary

Stanley C. Erck - Chief Executive Officer, President , Director and Member of Finance Committee

Frederick W. Driscoll - Chief Financial Officer, Principal Accounting Officer, Vice President and Treasurer

Louis Fries - Vice President of Clinical and Medical Affairs

Gregory M. Glenn - Chief Medical Officer and Senior Vice President

Analysts

Edward A. Tenthoff - Piper Jaffray Companies, Research Division

George B. Zavoico - McNicoll, Lewis & Vlak LLC, Research Division

Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division

Christopher Marai

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the Novavax Second Quarter Earnings Conference Call. [Operator Instructions] And as a reminder, this call is being recorded. I would now like to turn the conference over to your host, Mr. John Herrmann. Please go ahead, sir.

John A. Herrmann

Thank you. Good morning, everyone. This is John Herrmann, Vice President and General Counsel of Novavax. Thank you for joining us on today's second quarter 2012 financial results conference call. Both the earnings release from this morning and an archive of this earnings call can be found on the company's website at novavax.com.

On today's call are Novavax's President and CEO, Stan Erck; our Vice President and CFO, Fred Driscoll; our Chief Medical Officer, Dr. Greg Glenn; and our Vice President of Medical Affairs, Dr. Louis Fries.

Before we begin our prepared remarks, I'll remind you that we will be making forward-looking statements during this teleconference that may include financial, clinical or commercial projections. Statements relating to future financial or business performance, conditions or strategies and other financial and business matters including expectations regarding revenue, operating expenses, cash usage and clinical developments in anticipated milestones, are all forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.

If you liked this article you might like

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Biotech Movers: Alexion, Arena, Novavax

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering